((H&J news, December 18, 2018))in December 18th Wuhan United Pharmaceuticals executives came to our company to communicate. Our company President Meng, Tang Rui, and Wu Nan gave reception.

Firstly, both sides introduced their advantages and main business. Subsequently, the two sides conducted in-depth communication and discussion on the theme of "drug iteration (dosage form / dosage) and clinical research cooperation".

Through sincere and focused discussions, both sides agreed with cooperation in the theme of "drug iteration (dosage form / dosage) and clinical research cooperation". The two sides will strengthen business contacts in the future and form a good cooperative relationship.

Attachment: introduction of Wuhan United pharmaceutical industry

Wuhan United Pharmaceutical Co., Ltd. is a limited liability company registered in October 19, 1998 on the basis of the former Wuhan ninth pharmaceutical factory after asset restructuring and shareholding reform. It has been selected as the backbone enterprise of the modern Chinese medicine and technology industry (Hubei) base, and has won the title of "National Science and technology demonstration enterprise of modern Chinese medicine", "the top ten credit units of Hubei's market industry", and national high-tech enterprises. Over the past 5 years, the company's main revenue has maintained an average annual growth rate of 50%, showing an accelerating trend. In recent years, the number of patent applications has increased rapidly. In 2013, the company was awarded the title of gazelle enterprise in East Lake hi tech Development Zone.